From Rachel Glennerster’s old J-PAL blog post, a classic worth resharing: “charge for bednets or distribute them for free?”
In 2000 there was an intense argument about whether malarial insecticide-treated bednets (ITNs) should be given out for free. Some argued that charging for bednets would massively reduce take-up by the poor. Others argued that if people don’t pay for something, they don’t value it and are less likely use it. It was an evidence-free argument at the time.
Then, a series of studies in many countries testing many different preventative health products showed that even a small increase in price led to a sharp decline in product take-up. Pricing did not help target the product to those who needed it most, and people were not more likely to use a product if they paid for it. This cleared the way for a massive increase in free bednet distribution (Dupas 2011 and Kremer and Glennerster 2011).
There was a dramatic increase in malaria bednet coverage between 2000 and 2015 in sub-Saharan Africa. At the same time, there was a massive fall in the number of malarial cases. In Nature, Bhatt and colleagues estimate that the vast majority of the decline in malarial cases is due to the increase in ITNs. They estimate there were 450 million fewer cases of malaria due to ITNs and four million fewer deaths due to ITNs. The lesson here is that testing an important policy-relevant idea can have as much impact on peoples’ lives as testing a specific program.
From Rachel Glennerster’s old J-PAL blog post, a classic worth resharing: “charge for bednets or distribute them for free?”